Black Diamond Therapeutics
Filed with the SEC on · accession 0001701541-26-000030
BDTX filed a 8-K (current report) with the SEC on Nov 10, 2026. A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more.
Black Diamond Therapeutics announced its financial results for the nine months ended September 30, 2026, via a press release furnished as Exhibit 99.1 to its Form 8-K.
✦ Ask GOAX AI about this filing — what it means for BDTX, what changed since its last filings and what to watch next.
Try it free for 7 days🔔 Want to stay updated on new SEC filings for BDTX?
Click hereBDTX filed a 8-K (SEC filing). Black Diamond Therapeutics announced its financial results for the nine months ended September 30, 2026, via a press release furnished as Exhibit 99.1 to its Form 8-K.
A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more. The "Item" number tells you the topic (e.g. 2.02 results, 5.02 executive change, 1.01 new agreement, 1.03 bankruptcy). Exhibits (99.1 press release) usually hold the details.
Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A 8-K (current report): A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more.
Get alerts when BDTX files with the SEC, plus live charts, key levels and news for 13,000+ stocks.
Try SEPT free for 7 days